Effects of acetonylgeraniin A on changes in the cAMP content and stress- induced gastric lesions in mice stomachs

L. H. Tsai, Y. H. Lee, F. L. Hsu, C. F. Chen

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

The effect of acetonylgeraniin A (AGA) on changes in the levels of cyclic AMP and ulcer formation in cold-restraint stress (CRS)-induced gastric lesions as well as on the pylorus-ligated gastric acid secretion were studied in mice. Gastric lesions induced by CRS (duration from 0.5 h to 2.5 h) produced a marked timedependent increase in the cAMP content of the stomach. AGA (0.2 mg/kg and 0.4 mg/kg, i.p.) significantly attenuated the increase in the cAMP content of CRS-induced stomachs. AGA administered intraperitoneally (i.p.) and orally (p.o.) to mice at doses of 0.1-0.4 mg/kg and 0.8-1.6 mg/kg, respectively, exhibited a protective effect on the development of gastric lesions induced by CRS. AGA at 0.2 mg/kg (i.p.) or 1.6 mg/kg (p.o.) prevented the development of gastric ulcers by about 95 %. A high correlation (r = 0.715, p <0.001, i.p.; r = 0.882, p <0.001, p.o.) between AGA-treatment and reduction of CRS-induced ulcers was observed. AGA (0.1-2 mg/kg, p.o.) decreased total acidity and peptic activity in a dose-dependent manner in pylorus-ligated mice. These results suggest that 1) the changes in the cyclic AMP levels observed in CRS-induced stomachs may be associated with the formation of mucosal damage, 2) AGA effectively reduced gastric mucosal ulcerations in response to CRS, 3) the antiulcer activity of AGA may be related to a decrease in the cyclic AMP content and acid secretion in the stomach of mice. Thus, AGA may protect against the development of CRS- induced gastric lesions by regulating cAMP levels and acid secretion in the stomach.
原文英語
頁(從 - 到)91-102
頁數12
期刊Chinese Pharmaceutical Journal
48
發行號1
出版狀態已發佈 - 1996

指紋

Stomach
Cyclic AMP
Pylorus
Acids
Ulcer
acetonylgeraniin
Gastrointestinal Contents
Gastric Acid
Acidity
Stomach Ulcer
Digestion

ASJC Scopus subject areas

  • Bioengineering
  • Pharmaceutical Science

引用此文

Effects of acetonylgeraniin A on changes in the cAMP content and stress- induced gastric lesions in mice stomachs. / Tsai, L. H.; Lee, Y. H.; Hsu, F. L.; Chen, C. F.

於: Chinese Pharmaceutical Journal, 卷 48, 編號 1, 1996, p. 91-102.

研究成果: 雜誌貢獻文章

Tsai, L. H. ; Lee, Y. H. ; Hsu, F. L. ; Chen, C. F. / Effects of acetonylgeraniin A on changes in the cAMP content and stress- induced gastric lesions in mice stomachs. 於: Chinese Pharmaceutical Journal. 1996 ; 卷 48, 編號 1. 頁 91-102.
@article{fe61666556694414a17d3442bd35abad,
title = "Effects of acetonylgeraniin A on changes in the cAMP content and stress- induced gastric lesions in mice stomachs",
abstract = "The effect of acetonylgeraniin A (AGA) on changes in the levels of cyclic AMP and ulcer formation in cold-restraint stress (CRS)-induced gastric lesions as well as on the pylorus-ligated gastric acid secretion were studied in mice. Gastric lesions induced by CRS (duration from 0.5 h to 2.5 h) produced a marked timedependent increase in the cAMP content of the stomach. AGA (0.2 mg/kg and 0.4 mg/kg, i.p.) significantly attenuated the increase in the cAMP content of CRS-induced stomachs. AGA administered intraperitoneally (i.p.) and orally (p.o.) to mice at doses of 0.1-0.4 mg/kg and 0.8-1.6 mg/kg, respectively, exhibited a protective effect on the development of gastric lesions induced by CRS. AGA at 0.2 mg/kg (i.p.) or 1.6 mg/kg (p.o.) prevented the development of gastric ulcers by about 95 {\%}. A high correlation (r = 0.715, p <0.001, i.p.; r = 0.882, p <0.001, p.o.) between AGA-treatment and reduction of CRS-induced ulcers was observed. AGA (0.1-2 mg/kg, p.o.) decreased total acidity and peptic activity in a dose-dependent manner in pylorus-ligated mice. These results suggest that 1) the changes in the cyclic AMP levels observed in CRS-induced stomachs may be associated with the formation of mucosal damage, 2) AGA effectively reduced gastric mucosal ulcerations in response to CRS, 3) the antiulcer activity of AGA may be related to a decrease in the cyclic AMP content and acid secretion in the stomach of mice. Thus, AGA may protect against the development of CRS- induced gastric lesions by regulating cAMP levels and acid secretion in the stomach.",
keywords = "Acetonylgeraniin A, Cold- restraint stress, Cyclic AMP, Gastric lesion, Peptic activity",
author = "Tsai, {L. H.} and Lee, {Y. H.} and Hsu, {F. L.} and Chen, {C. F.}",
year = "1996",
language = "English",
volume = "48",
pages = "91--102",
journal = "Taiwan Pharmaceutical Journal",
issn = "1016-1015",
publisher = "臺灣藥學會",
number = "1",

}

TY - JOUR

T1 - Effects of acetonylgeraniin A on changes in the cAMP content and stress- induced gastric lesions in mice stomachs

AU - Tsai, L. H.

AU - Lee, Y. H.

AU - Hsu, F. L.

AU - Chen, C. F.

PY - 1996

Y1 - 1996

N2 - The effect of acetonylgeraniin A (AGA) on changes in the levels of cyclic AMP and ulcer formation in cold-restraint stress (CRS)-induced gastric lesions as well as on the pylorus-ligated gastric acid secretion were studied in mice. Gastric lesions induced by CRS (duration from 0.5 h to 2.5 h) produced a marked timedependent increase in the cAMP content of the stomach. AGA (0.2 mg/kg and 0.4 mg/kg, i.p.) significantly attenuated the increase in the cAMP content of CRS-induced stomachs. AGA administered intraperitoneally (i.p.) and orally (p.o.) to mice at doses of 0.1-0.4 mg/kg and 0.8-1.6 mg/kg, respectively, exhibited a protective effect on the development of gastric lesions induced by CRS. AGA at 0.2 mg/kg (i.p.) or 1.6 mg/kg (p.o.) prevented the development of gastric ulcers by about 95 %. A high correlation (r = 0.715, p <0.001, i.p.; r = 0.882, p <0.001, p.o.) between AGA-treatment and reduction of CRS-induced ulcers was observed. AGA (0.1-2 mg/kg, p.o.) decreased total acidity and peptic activity in a dose-dependent manner in pylorus-ligated mice. These results suggest that 1) the changes in the cyclic AMP levels observed in CRS-induced stomachs may be associated with the formation of mucosal damage, 2) AGA effectively reduced gastric mucosal ulcerations in response to CRS, 3) the antiulcer activity of AGA may be related to a decrease in the cyclic AMP content and acid secretion in the stomach of mice. Thus, AGA may protect against the development of CRS- induced gastric lesions by regulating cAMP levels and acid secretion in the stomach.

AB - The effect of acetonylgeraniin A (AGA) on changes in the levels of cyclic AMP and ulcer formation in cold-restraint stress (CRS)-induced gastric lesions as well as on the pylorus-ligated gastric acid secretion were studied in mice. Gastric lesions induced by CRS (duration from 0.5 h to 2.5 h) produced a marked timedependent increase in the cAMP content of the stomach. AGA (0.2 mg/kg and 0.4 mg/kg, i.p.) significantly attenuated the increase in the cAMP content of CRS-induced stomachs. AGA administered intraperitoneally (i.p.) and orally (p.o.) to mice at doses of 0.1-0.4 mg/kg and 0.8-1.6 mg/kg, respectively, exhibited a protective effect on the development of gastric lesions induced by CRS. AGA at 0.2 mg/kg (i.p.) or 1.6 mg/kg (p.o.) prevented the development of gastric ulcers by about 95 %. A high correlation (r = 0.715, p <0.001, i.p.; r = 0.882, p <0.001, p.o.) between AGA-treatment and reduction of CRS-induced ulcers was observed. AGA (0.1-2 mg/kg, p.o.) decreased total acidity and peptic activity in a dose-dependent manner in pylorus-ligated mice. These results suggest that 1) the changes in the cyclic AMP levels observed in CRS-induced stomachs may be associated with the formation of mucosal damage, 2) AGA effectively reduced gastric mucosal ulcerations in response to CRS, 3) the antiulcer activity of AGA may be related to a decrease in the cyclic AMP content and acid secretion in the stomach of mice. Thus, AGA may protect against the development of CRS- induced gastric lesions by regulating cAMP levels and acid secretion in the stomach.

KW - Acetonylgeraniin A

KW - Cold- restraint stress

KW - Cyclic AMP

KW - Gastric lesion

KW - Peptic activity

UR - http://www.scopus.com/inward/record.url?scp=0029945791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029945791&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029945791

VL - 48

SP - 91

EP - 102

JO - Taiwan Pharmaceutical Journal

JF - Taiwan Pharmaceutical Journal

SN - 1016-1015

IS - 1

ER -